Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 147, Issue 1, Pages 97-101Publisher
WILEY
DOI: 10.1111/j.1365-2141.2009.07837.x
Keywords
Hodgkin lymphoma; HDAC inhibitor; LBH589; panobinostat
Categories
Ask authors/readers for more resources
P>There are few treatment options for patients with Hodgkin Lymphoma (HL) who relapse after conventional therapies. Panobinostat is an orally available pan deacetylase inhibitor with evidence of activity in myeloid malignancies and cutaneous T cell lymphoma. Thirteen HL patients were treated with escalating doses of this novel agent in a phase IA/II multicentre study. A computed tomography partial response was achieved in 5/13(38%), and a metabolic response by
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available